Publications

Both small and large firms are essential to America’s innovation system because they specialize in different forms of innovation. Congress should double the regular R&D tax credit to 40 percent and reduce the red tape associated with claiming it.

Manufacturing labor productivity growth is a key driver of the United States’ long-term economic performance and global competitiveness, but it has slowed sharply since 2005. Congress should provide a 25 percent tax credit to firms adopting productivity-enhancing technologies to help reverse this slowdown.

Canada should significantly expand commercialization-focused grant programs through the Canadian Institutes of Health Research (CIHR) and increase Canada’s overall health science research investments to a scale commensurate with global competition.

German exports to China as a share of GDP have declined by more than 40 percent since 2021, while the German labor force has seen a decline of more than 400,000 jobs linked to exports to China.

Canada funds university research but gives universities too little reason to turn that into Canadian firms, patents, and industrial capacity. To better align their incentives with national goals, funding should flow in part on standardized commercialization outcomes, with universities left to decide how to deliver them.

China has utilized numerous illegitimate tools in pursuit of global leadership in biopharmaceutical manufacturing, including IP theft, forced labor, and stealing genetic information. This must be met with a swift and forceful response from U.S. policymakers.

The United States is the global power in space, but insufficient spaceport infrastructure threatens the growth of the American space industry. Congress, NASA, and Space Force must address the problem before it undermines U.S. leadership.

China is becoming an increasingly capable competitor in the global pharmaceutical industry, with growing strengths at every level of the biopharmaceutical supply chain. Responding to this challenge will require a comprehensive, whole-of-government strategy, with strong cross-agency collaboration, to advance U.S. biopharmaceutical competitiveness.

South Korea's discriminatory treatment of American tech firms exposes a critical gap in the U.S.-Korea relationship. The two countries should negotiate a dedicated mechanism for resolving bilateral digital trade disputes.

The United States risks falling further behind China in humanoid robotics unless policymakers adopt a national strategy to strengthen domestic production, accelerate adoption, and scale the industry.